A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid Tumors
A study for patients with advanced solid tumors using study drug Nivolumab
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAQ8652
U.S. Govt. ID: NCT02754141
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to test the safety, anti-tumor activity, and the ability of a new investigational drug called BMS-986179 (also known as anti-CD73) plus nivolumab (also known as BMS-936558) to block the protein CD73 from producing high amounts of a product known as adenosine which blocks your immune system from killing your cancer cells. Nivolumab is an anti-cancer drug that has been approved in the US, Canada and other countries for several different type of cancers.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with advanced solid tumors? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator